Pleurodynia Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Diagnosis, By Treatment, By Mode of Administration, By End-User, By Region & Competition, 2021-2031F

The Global Pleurodynia Treatment Market is projected to expand from USD 152.11 Million in 2025 to USD 207.48 Million by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 5.31%. This market encompasses therapeutic and symptomatic management strategies for Bornholm disease, a viral illness primarily caused by Group B Coxsackieviruses that manifests as acute spasmodic chest and abdominal pain. Key drivers of this growth include the rising incidence of enteroviral infections and advancements in molecular diagnostics, which enable quicker differentiation of viral myalgia from more critical cardiac or pulmonary conditions. For instance, the Taiwan Centers for Disease Control reported over 12,350 weekly outpatient and emergency visits for enterovirus infections in January 2025, underscoring the ongoing clinical burden that fuels demand for analgesic and anti-inflammatory treatments. Market expansion is, however, challenged by frequent misdiagnosis of pleurodynia, as its non-specific symptoms often mimic life-threatening emergencies like myocardial infarction or pulmonary embolism. This diagnostic uncertainty often leads healthcare providers to prioritize extensive cardiac workups over immediate viral symptom management, thereby delaying appropriate supportive care and constricting the commercial viability of targeted pleurodynia treatments. Additionally, the prevalence of low-cost generic non-steroidal anti-inflammatory drugs as the standard of care creates a low-margin environment, which discourages significant pharmaceutical investment in developing novel proprietary formulations specifically for this indication.

Market Driver

The increasing prevalence of Coxsackie B virus and other enteroviral infections serves as a primary driver for the Global Pleurodynia Treatment Market. The rising number of cases necessitates robust symptomatic management and precise diagnostic differentiation, compelling healthcare systems to enhance analgesic protocols and implement rapid testing to distinguish Bornholm disease from other acute chest pain etiologies. In September 2025, weekly outpatient and emergency visits for enterovirus infections in Taiwan reached 8,313, as reported by the Taiwan Centers for Disease Control, indicating a sustained need for supportive care even outside traditional peak seasons. The complexity introduced by diverse circulating viral strains, such as Enterovirus D68 accounting for 61.6% of reported enterovirus specimens in June 2025 according to the U.S. Centers for Disease Control and Prevention, further emphasizes the need for refined treatment approaches. Parallel to this, growing research and development investments in broad-spectrum antiviral therapeutics and vaccines are transforming the market by promoting the creation of new agents capable of targeting the Picornaviridae family, including Group B Coxsackieviruses. Public and private funding is increasingly channeled into translating basic virology research into clinical applications, aiming to introduce targeted therapies that offer more than the current non-specific pain relief. An example of this is the approximate $11.8 million awarded by the Advanced Research Projects Agency for Health (ARPA-H) to Mount Sinai Medical Center in October 2025 for developing broad-spectrum antiviral therapies, as reported by BioWorld. Such significant financial backing is crucial for advancing pipeline candidates through clinical trials, potentially introducing the first disease-modifying treatments for pleurodynia and substantially boosting the commercial potential of the sector.

Market Challenge

A significant impediment to the growth of the Global Pleurodynia Treatment Market is the frequent misdiagnosis of Bornholm disease, primarily due to its clinical presentation mimicking life-threatening cardiac events. The spasmodic chest pain characteristic of pleurodynia often closely resembles symptoms of myocardial infarction or pulmonary embolism, leading healthcare providers to prioritize extensive cardiac exclusionary tests over immediate viral symptom management. This diagnostic ambiguity delays the appropriate administration of analgesic or anti-inflammatory therapies, thereby narrowing the commercial opportunity for pleurodynia-specific interventions and diminishing the overall market volume for targeted treatments. This diagnostic challenge is particularly problematic given the substantial underlying prevalence of the causative viral agents, which often goes unrecognized in the context of specific pleurodynia treatment demand. For instance, the UK Health Security Agency reported an enterovirus and rhinovirus positivity rate of approximately 20.3% in monitored respiratory samples in November 2025. Despite such high viral circulation, the market struggles to capitalize on this patient base because a large proportion of these cases are clinically classified as non-specific chest pain or cardiac rule-outs rather than confirmed enteroviral myalgia, consequently suppressing the addressable revenue potential for the market.

Market Trends

The clinical management of pleurodynia is undergoing a rapid transformation toward non-opioid analgesic therapies, driven by the critical need to alleviate severe spasmodic chest pain without the associated risks of opioid dependence. This market shift is characterized by the emergence and commercialization of novel sodium channel inhibitors that specifically target peripheral pain signals linked to viral myalgia, offering a more sophisticated alternative to the generic non-steroidal anti-inflammatory drugs currently used as standard care. A notable development in this area was the U.S. Food and Drug Administration's approval of suzetrigine, a first-in-class oral NaV1.8 pain signal inhibitor, in January 2025, as reported by Vertex Pharmaceuticals. This drug directly addresses the acute pain management needs of approximately 80 million patients annually in the U.S., providing healthcare providers with a potent, targeted therapeutic option that aligns with the increasing emphasis on opioid-sparing protocols for acute viral conditions. Concurrently, the application of mRNA technology for enteroviral infections is revolutionizing the development of both prophylactic and therapeutic interventions for the Picornaviridae family, which includes Group B Coxsackieviruses. This trend leverages the inherent adaptability of mRNA platforms to create vaccines that can be quickly reformulated to match circulating strains, significantly reducing the lengthy development timelines associated with traditional inactivated vaccine candidates. Research published in Frontiers in Immunology in February 2025, for example, demonstrated that a nucleoside-modified mRNA vaccine candidate targeting the VP1 protein of Enterovirus A71 provided 100% protection against lethal viral challenge in preclinical models. Such promising results underscore the potential of mRNA technology to deliver precise protection against the specific viral agents responsible for Bornholm disease, marking a shift towards disease-modifying treatments beyond mere symptomatic relief.

Key Market Players

• Bristol-Myers Squibb Co
• F. Hoffmann-La Roche Ltd
• Pfizer Inc
• Sanofi SA
• Johnson & Johnson
• Merck & Co Inc.
• GlaxoSmithKline PLC
• Reckitt Benckiser PLC
• Bayer AG
• Novartis AG

Report Scope

In this report, the Global Pleurodynia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pleurodynia Treatment Market, By Diagnosis

• Blood test
• Culture test
• X-ray

Pleurodynia Treatment Market, By Treatment

• Analgesics or Painkillers
• Immunoglobulin

Pleurodynia Treatment Market, By Mode of Administration

• Oral
• Injections or infusion

Pleurodynia Treatment Market, By End-User

• Hospitals
• Pharmacy
• Others

Pleurodynia Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pleurodynia Treatment Market.

Available Customizations:

Global Pleurodynia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).